Background Low dose methotrexate
Abstract
Background Low dose methotrexate has become established in the treatment of refractory rheumatoid arthritis. Until recently it has been considered that the use of a low dose regimen (<20 mg/ week) would avoid the pulmonary toxicity associated with the higher doses prescribed in malignant disease. Although initial experience with low dose methotrexate was encouraging, an increasing number of cases of an acute, life threatening pneumonitis are being reported in patients with Methotrexate induced pneumonitis was considered likely and he was advised to discontinue methotrexate and to report any subsequent deterioration without delay.
Four days later he presented with increasing dyspnoea. On examination he was cyanosed and dyspnoeic at rest with basal inspiratory creptitations. The haemoglobin concentration was 13-0 g/dl and white blood cells 12-7 x 109/1 with no eosinophilia. The results of arterial blood gas analysis (FIo2 21%) were: pH 7 45, Paco2 4-02 kPa, Pao2 5 18 kPa. A repeat chest radiograph showed increased interstitial shadowing. Cultures of sputum and blood samples were negative and serological tests on convalescent phase serum showed no rise in titres of antibodies to atypical agents.
Ampicillin and hydrocortisone succinate (200 mg six hourly) were administered intravenously with oral prednisolone 60 mg daily.
By the fourth day he had considerably improved and oxygen saturation was consistently above 95% (FIo2 28%). Ampicillin and hydrocortisone were discontinued and oral prednisolone continued. He was discharged after 12 days taking prednisolone 30 mg daily, which was tailed off over the subsequent two months.
When reviewed four months later he was symptom free, though troubled by a recurrence of articular symptoms. A chest radiograph and results of repeat pulmonary function tests were normal. PATIENT 3 In November 1988 a 67 year old woman with a 15 year history of seropositive rheumatoid arthritis was admitted with a short history of dyspnoea.
Intramuscular gold injections and chloroquine had been of limited value and she continued to have symptoms despite oral prednisolone. In August 1988 she was started on methotrexate 10 mg/week (total dose 130 mg), with moderate symptomatic improvement. In the two weeks before admission she became increasingly dyspnoeic. A chest radiograph showed diffuse interstitial and alveolar infiltration.
On examination she was cyanosed and dyspnoeic at rest. Her temperature was 39 0°C, pulse 60/min, and blood pressure 105/70 mm Hg. Examination of her chest indicated harsh inspiratory creptitations throughout both lung fields.
The haemoglobin concentration was 8-9 g/dl and white blood cells 6-6 x 109/1, with 12%' eosinophils. The erythrocyte sedimentation rate was 1 10 mm in the first hour. The results of arterial blood gas analysis (FIO2 40%) were: pH 7 42, Paco2 37 kPa, Pao2 7 21 kPa. Cultures of sputum and blood samples were negative and serological tests on acute and convalescent phase serum showed no rise in titres of antibodies to atypical agents.
Methotrexate was stopped and broad spectrum antibodies were administered intravenously with oral prednisolone 100 mg daily. Her condition thereafter rapidly improved with both clinical and radiological resolution. She returned to the referring hospital after 10 days taking prednisolone 30 mg daily, which was tailed off over two months.
When reviewed two months later she was symptom free and her chest radiograph normal. PATIENT 4 In December 1990 a 75 year old woman with an 11 year history of seropositive rheumatoid arthritis was admitted with dyspnoea. In August 1988 she had been started on methotrexate 5 mg/week (total dose 600 mg), with an excellent clinical response. Two months before admission she developed a non-productive cough, fever, and increasing dyspnoea, which had progressed despite antibiotics.
On admission she was cyanosed and dyspnoeic at rest. She was afebrile. Her pulse was 120/min and blood pressure 150/80 mm Hg. (fig 2A) . Cultures of sputum and blood samples were negative and serological tests on convalescent phase serum showed no rise in titres of antibodies to atypical agents.
Methotrexate was stopped and she was started on prednisolone 40 mg daily. There was considerable clinical and radiological resolution over the next two weeks and she was discharged on a reducing course of corticosteroids. By three months she was symptom free. A chest radiograph confirmed radiological resolution ( fig 2B) . PATIENT 5 In March 1991 a 76 year old man with an 11 year history of seropositve rheumatoid arthritis was admitted with cough and increasing dyspnoea. In November 1990 he was started on methotrexate 10 mg/week (total 180 mg). A marginal response was observed.
Two months before admission he had noted sweats, fever, and general malaise associated with anorexia and weight loss. Ten days before admission he had developed a non-productive cough with increasing dyspnoea.
Other medications included prednisolone 5 17 As methotrexate has been shown to accumulate preferentially in the lung,i8 and clinical resolution may follow dose reduction,19 it has been suggested that a direct cytotoxic action may be important in some instances. 4 Acute pulmonary toxicity appears, however, to be unrelated to either the dose or the duration of treatment. One important variable appears to be the frequency of administration since patients receiving daily or even weekly doses have a higher risk of toxicity than those receiving the drug less frequently. 20 Two recent prospective studies have addressed the incidence of pulmonary toxicity during low dose methotrexate treatment for active rheumatoid arthritis. Hanrahan et ali described one such case from a cohort of 128 patients followed for up to four years, and Furst et a122 reported no instances of acute pneumonitis from 45 patients during a treatment period extending over three years. Retrospective analysis based on several series, however, would suggest an incidence of 3- 5.5% 9 16 response may be observed in selected patients. Accordingly, it is disappointing that, despite low dose regimens, methotrexate may be associated with acute life threatening pneumonitis. We would suggest that before starting treatment patients should have a full clinical, radiological, and physiological assessment for detection of occult lung disease. Further prospective studies are required to examine both the incidence of acute pneumonitis during low dose treatment and potential risk factors for its development.
